首页> 外文期刊>Global Pediatric Health >The Effectiveness and Safety of a Homeopathic Medicinal Product in Pediatric Upper Respiratory Tract Infections With Fever: A Randomized Controlled Trial
【24h】

The Effectiveness and Safety of a Homeopathic Medicinal Product in Pediatric Upper Respiratory Tract Infections With Fever: A Randomized Controlled Trial

机译:顺势疗法药物在小儿上呼吸道感染发烧的有效性和安全性:随机对照试验。

获取原文
           

摘要

We investigated the clinical effectiveness of a homeopathic add-on therapy in a pediatric subpopulation with upper respiratory tract infections (URTI) in a randomized, controlled, multinational clinical trial. Patients received either on-demand symptomatic standard treatment (ST-group) or the same ST plus a homeopathic medication (Influcid; IFC-group) for 7 days. Outcome assessment was based on symptom and fever resolution and the Wisconsin Upper Respiratory Symptom Survey–21 (WURSS-21). A total of 261 pediatric (12 years) patients (130 IFC-group; 131 ST-group) were recruited in Germany and the Ukraine. The IFC-group used less symptomatic medication, symptoms resolved significantly earlier (P = .0001), had higher proportions of fever-free children from day 3 onwards, and the WURSS-assessed global disease severity was significantly less (P .0001) during the entire URTI episode. One adverse event (vomiting) was possibly related to IFC. IFC as add-on treatment in pediatric URTI reduced global disease seve...
机译:在一项随机,对照,跨国的临床试验中,我们研究了顺势疗法附加疗法在上呼吸道感染(URTI)患儿亚群中的临床效果。患者接受按需对症标准治疗(ST组)或相同的ST加顺势疗法药物(Influcid; IFC组)治疗7天。结果评估基于症状和发烧的缓解以及威斯康星州上呼吸道症状调查–21(WURSS-21)。在德国和乌克兰,共招募了261名小儿(<12岁)患者(130名IFC组; 131名ST组)。 IFC组使用较少的对症药物,症状较早解决(P = .0001),从第3天起无发热儿童比例更高,而WURSS评估的全球疾病严重程度则显着降低(P <.0001)在整个URTI节目中。一项不良事件(呕吐)可能与国际金融公司有关。 IFC作为儿科URTI的附加治疗可减少全球疾病

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号